Ahmad I, 2000, J Cardiovasc Risk, 7, 303, 10.1177/204748730000700502
10.1056/NEJM199304293281702
Roche HM, 2000, J Cardiovasc Risk, 7, 317, 10.1177/204748730000700504
10.1080/10408369891234255
Austin MA., 1999, Lipoproteins in Health and Disease, 611
10.1001/jama.1996.03540110029028
10.1097/00043798-199604000-00014
10.2165/00129784-200101050-00003
10.1016/S0140-6736(95)92118-4
Laasko M, 1995, Diabetes Rev, 3, 463
Oluwatoyin M, 2001, AIDS Reader, 11, 263
Stein EA, 1998, Am J Cardiol, 69B
10.1016/S0002-9149(00)01012-2
10.1016/S0002-9149(98)00010-1
10.1161/01.CIR.98.19.2088
10.1007/s11883-001-0015-x
10.1016/S0024-3205(00)00680-9
10.1016/S0021-9150(99)00352-4
Freeman DM, 2001, Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Project. Circulation, 103, 357
10.1046/j.1365-2362.2000.00734.x
10.2165/00003088-199834020-00003
10.2165/00003088-199834050-00006
Jeng CY, 1996, J Clin Endocrinol Metab, 81, 2550
10.1016/S0149-2918(96)80021-X
10.1007/s11883-001-0006-y
Tannous M, 1999, Thromb Haemost, 82, 1390, 10.1055/s-0037-1614841
Cortellaro M, 2000, Fluvastatin Alone and in Combination Treatment. Thromb Haemost, 83, 549
10.1097/00001721-199906000-00006
Ridker PM, 1999, The Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 100, 230
10.1161/01.CIR.103.9.1194
10.1016/S0008-6363(01)00227-9
10.1016/S0021-9150(97)00252-9
10.1016/S0002-9149(00)01516-2
10.1056/NEJM199908053410604
10.1056/NEJM198711123172001
The BIP study group, 2000, The Bezafibrate Infarct Prevention (BIP) Study. Circulation, 102, 21
Committee of Principal Investigators, 1980, Report of the Committee of Principal Investigators. Lancet, 2, 379
10.1111/j.1365-2796.1994.tb01029.x
10.1161/01.CIR.98.23.2513
10.1002/(SICI)1096-9136(199707)14:7<513::AID-DIA427>3.0.CO;2-S
10.1161/01.CIR.102.16.1893
10.2165/00003088-199732050-00005
10.1016/S0378-4274(02)00010-3
10.1111/j.1365-2362.1995.tb01530.x
10.1097/00004836-199512000-00027
10.2165/00002018-199819050-00003
10.1046/j.1365-2125.1999.00846.x
10.1177/00912700022008874
10.1097/00041433-199612000-00008
10.1016/S0140-6736(98)00022-1
10.1016/S0140-6736(05)79858-5
Kehely A, 1995, Q J Med, 88, 421
10.1016/S0002-9149(97)00430-X
10.1016/S0021-9150(00)00726-7
10.1046/j.1365-2796.2000.00646.x
10.1016/S0002-9149(99)00030-2
10.1016/S0167-5273(99)00013-3
10.1016/S0021-9150(00)00379-8
10.1097/00005344-200003000-00003
Vergoulas G, 2000, Transplant Int, 13, S64–S67
10.1016/S0026-0495(99)90009-4
10.1016/S0140-6736(02)11203-7
10.1016/0026-0495(90)90256-C
10.1016/S0140-6736(05)65951-X
10.1016/S0002-9149(01)02208-1
Steiner G, 2000, Diabetes Care, 23, B49
10.1056/NEJM200202143460721
10.1016/S0002-9149(02)02436-0
10.1016/S0140-6736(02)09327-3
10.1056/NEJM199701163360301
10.1185/030079902125000165
10.1016/S0002-9149(01)02258-5
10.1001/archinte.162.14.1568
Ito MK, 2002, Am J Manag Care, 8, S315
10.1007/s11886-999-0030-z
10.1016/S0950-351X(95)80177-4
Steinmetz KL, 2002, Am J Health Syst Pharm, 59, 932, 10.1093/ajhp/59.10.932
10.1097/00132580-200101000-00009
Miettinen TA, 2001, Int J Clin Pract, 55, 710, 10.1111/j.1742-1241.2001.tb11168.x
10.1046/j.1365-2125.2002.01633.x
10.1161/01.CIR.0000018744.58460.62
Karen-Morag N, 2002, U. Low and high density lipoprotein cholesterol and ischemic cerebrovascular disease: the Bezafibrate Infarction Prevention registry. Arch Intern Med, 162, 993
10.1016/S0008-6363(01)00383-2
Athyros VG, 2002, The GREek Atorvastatin and Coronary-heartdisease Evaluation (GREACE) Study. Curr Med Res Opin, 18, 220
10.1185/030079902125000778
10.1016/S0167-5273(01)00625-8
Wierzbicki AS, 2002, Another method of reducing blood pressure? J Hum Hypertens, 16, 753
